How Prolaio Is Transforming Heart Health With Real-World Data and Clinical Intelligence

Prolaio’s Vision for the Future of Heart Health Care

Tassos Gianakakos was working at a precision medicine biotech company called MyoKardia when he saw critical decisions about complex heart diseases being made using thin, episodic data. 

That’s when he realized the need to make continuous, real-world heart data readily available in everyday practice and rigorous clinical studies. So, he and Jay Edelberg, a colleague at MyoKardia, came together to create Prolaio, a clinical intelligence company dedicated to unlocking access to continuous, predictive and shareable heart data. 

Since its inception in 2022, the company has expanded its influence on the industry; most notably, when Prolaio was acquired by cardiovascular drug development company Kardigan earlier this year. 

“Today, as an independently functioning company within Kardigan, we’re creating a world-leading heart health company of the future with one of the largest curated cardiovascular data sets, FDA-cleared software and proprietary algorithms all with the goal to help partners design better trials, discover more targeted medicines, and keep people out of the hospital by preventing avoidable heart events in the first place,” Gianakakos said. 

Prolaio’s platform was designed to function as long-term infrastructure, capable of bringing people with cardiovascular diseases closer to cures. And while some aspects of the organization have transformed over the years, Gianakakos said, its founding mission — the belief that meaningful, real-world data can fundamentally change the pace and quality of cardiovascular innovation — remains the same.

“From day one, we’ve been patient-centered and science-driven — committed to pairing rigorous clinical evidence with advanced analytics to enable decisions that are grounded in what’s actually happening in people’s lives, not just what we see during brief clinic visits,” he said.

Below, Gianakakos shares more about the founding of Prolaio, its continuous evolution and its impact on the heart health care space. 

 

 

The Moment That Sparked Prolaio’s Creation

Prolaio was born from a simple but urgent realization: Cardiology will never catch up to the precision and speed patients deserve until we can continuously capture and intelligently use real-world heart data to guide therapies, not just monitor symptoms.

 

 

Prolaio’s First Major Breakthrough 

Our first real milestone was building and validating an FDA-cleared remote monitoring platform that could reliably capture high-density cardiovascular signals at scale and deploying it in multi-center studies around the world. That early proof point showed that top cardiologists and researchers could trust our data and algorithms, and it set the foundation for what has now become one of the industry’s most robust curated cardiovascular data sets. Today, that platform is used in clinical trials with partners like Kardigan, with more capabilities than ever, as each study adds new signals and outcomes. That data continuously strengthens our models, informs smarter trials, and helps target cardiovascular therapies with increasing precision.

 

Challenges That Shaped Prolaio’s Early Growth

In the early days, it was easy for people to see us as “just another remote monitoring vendor” rather than a clinical intelligence platform built to fundamentally change how cardiovascular research and care are conducted. We overcame that by doubling down on scientific rigor, building a quality system capable of supporting multiple FDA clearances, proving trial-enrichment value with real studies, and demonstrating how our high-density, longitudinal data could reduce noise, increase statistical power, and meaningfully de-risk cardiovascular drug development. That body of evidence reframed us from a tool to an engine for discovery.

 

 

How Prolaio’s Mission Has Evolved — and What Has Stayed the Same

We started with a broad ambition to “radically revolutionize heart care to save more lives” and become the leading brand fighting the world’s number one killer. Over time, that mission has sharpened into a more precise mandate: to transform real-world heart data into faster therapeutic discovery today and precision cardiovascular care for functional cures tomorrow. Our focus has expanded from enabling better daily care to also powering smarter clinical trials and drug development, in partnership with companies like Kardigan. But the throughline remains unchanged: Use better data and better tools to get patients to better outcomes, faster.

 

“Our focus has expanded from enabling better daily care to also powering smarter clinical trials and drug development, in partnership with companies like Kardigan. But the throughline remains unchanged: Use better data and better tools to get patients to better outcomes, faster.”

 

The value that has never moved an inch is our belief that meaningful, real-world data in the hands of cardiologists, researchers and patients can fundamentally change the pace and quality of cardiovascular innovation that leads to better care. From day one, we’ve been patient-centered and science-driven — committed to pairing rigorous clinical evidence with advanced analytics to enable decisions that are grounded in what’s actually happening in people’s lives, not just what we see during brief clinic visits.

 

Frequently Asked Questions